NASDAQ:ANGO - AngioDynamics Stock Price, Price Target & More Sign in or create an account to add this stock to your watchlist. Get Started $20.60 +0.10 (+0.49 %) (As of 07/15/2018 04:00 PM ET)Previous Close$20.60Today's Range$20.10 - $20.6552-Week Range$14.97 - $23.95Volume466,407 shsAverage Volume391,458 shsMarket Capitalization$758.18 millionP/E Ratio28.22Dividend YieldN/ABeta1.03 Company ProfileFinancialsAnalyst RatingsEarnings HistoryInsider TradesHeadlinesOptions ChainSEC FilingsSocial MediaChart Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email AngioDynamics, Inc. designs, manufactures, and sells various medical, surgical, and diagnostic devices for the treatment of peripheral vascular disease, vascular access, and for use in oncology and surgical settings in the United States and internationally. The company provides manifolds, contrast management systems, closed fluid systems, guidewires, disposable transducers, and interventional accessories that help clinicians in the diagnosis and treatment of cardiovascular and peripheral vascular diseases; VenaCure EVLT laser system products to treat superficial venous diseases; Asclera drug for treating uncomplicated spider and reticular veins of the lower extremities; and Sotradecol drugs for treating small uncomplicated varicose veins of the lower extremities. It also offers AngioVac venous drainage system that includes venous drainage cannula for the removal of fresh, soft thrombi, or emboli during extracorporeal bypass; and cardiopulmonary bypass circuit for use in procedures during extracorporeal circulatory support. In addition, the company provides thrombolytic catheters to deliver thrombolytic agents; angiographic products and accessories for use in during peripheral vascular interventional procedures; drainage products, which drain abscesses and other fluid pockets; and micro access sets. Further, it offers peripherally inserted central catheters; ports that are implantable devices for the central venous administration; and dialysis products. Additionally, the company provides microwave ablation products; radiofrequency ablation products for ablating solid cancerous or benign tumors; and NanoKnife ablation systems for the surgical ablation of soft tissues. It sells and markets its products to interventional radiologists, interventional cardiologists, vascular surgeons, urologists, and interventional and surgical oncologists directly, as well as through distributor relationships. The company was founded in 1988 and is headquartered in Latham, New York. Receive ANGO News and Ratings via Email Sign-up to receive the latest news and ratings for ANGO and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Surgical & medical instruments Sub-IndustryHealth Care Equipment SectorMedical SymbolNASDAQ:ANGO CUSIP03475V10 Webwww.angiodynamics.com Phone518-795-1400 Debt Debt-to-Equity Ratio0.16 Current Ratio2.93 Quick Ratio1.84 Price-To-Earnings Trailing P/E Ratio28.22 Forward P/E Ratio23.95 P/E Growth1.61 Sales & Book Value Annual Sales$344.29 million Price / Sales2.20 Cash Flow$1.3788 per share Price / Cash14.94 Book Value$14.74 per share Price / Book1.40 Profitability EPS (Most Recent Fiscal Year)$0.74 Net Income$5 million Net Margins4.74% Return on Equity5.21% Return on Assets3.94% Miscellaneous Employees1,250 Outstanding Shares36,810,000Market Cap$758.18 AngioDynamics (NASDAQ:ANGO) Frequently Asked Questions What is AngioDynamics' stock symbol? AngioDynamics trades on the NASDAQ under the ticker symbol "ANGO." How were AngioDynamics' earnings last quarter? AngioDynamics, Inc. (NASDAQ:ANGO) released its quarterly earnings results on Wednesday, July, 11th. The medical instruments supplier reported $0.20 earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of $0.21 by $0.01. The medical instruments supplier had revenue of $88.30 million for the quarter, compared to analysts' expectations of $89.02 million. AngioDynamics had a net margin of 4.74% and a return on equity of 5.21%. The firm's revenue for the quarter was up 1.6% compared to the same quarter last year. View AngioDynamics' Earnings History. When is AngioDynamics' next earnings date? AngioDynamics is scheduled to release their next quarterly earnings announcement on Wednesday, September, 26th 2018. View Earnings Estimates for AngioDynamics. What guidance has AngioDynamics issued on next quarter's earnings? AngioDynamics issued an update on its FY19 earnings guidance on Wednesday, July, 11th. The company provided earnings per share guidance of $0.82-0.86 for the period, compared to the Thomson Reuters consensus EPS estimate of $0.91. The company issued revenue guidance of $344-349 million, compared to the consensus revenue estimate of $347.79 million. What price target have analysts set for ANGO? 6 equities research analysts have issued 1 year target prices for AngioDynamics' stock. Their forecasts range from $16.00 to $20.00. On average, they expect AngioDynamics' stock price to reach $17.4433 in the next year. This suggests that the stock has a possible downside of 15.3%. View Analyst Ratings for AngioDynamics. What is the consensus analysts' recommendation for AngioDynamics? 6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for AngioDynamics in the last year. There are currently 5 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." Who are some of AngioDynamics' key competitors? Some companies that are related to AngioDynamics include Novocure (NVCR), Merit Medical Systems (MMSI), NuVasive (NUVA), Irhythm Technologies (IRTC), Nevro (NVRO), Mazor Robotics (MZOR), Glaukos (GKOS), Luminex (LMNX), Tandem Diabetes Care (TNDM), Cardiovascular Systems (CSII), Atrion (ATRI), Orthofix International (OFIX), Cryolife (CRY), OraSure Technologies (OSUR) and Intersect ENT (XENT). Who are AngioDynamics' key executives? AngioDynamics' management team includes the folowing people: Mr. James C. Clemmer, Pres, CEO & Director (Age 54)Mr. Michael C. Greiner, Exec. VP, CFO & Principal Accounting Officer (Age 45)Mr. Stephen A. Trowbridge, Sr. VP, Gen. Counsel & Assistant Sec. (Age 44)Mr. Chad T. Campbell, Sr. VP & Gen. Mang. of Global Vascular Access (Age 47)Mr. Robert A. Simpson, Sr. VP Peripheral Vascular (Age 46) Has AngioDynamics been receiving favorable news coverage? Headlines about ANGO stock have trended somewhat positive recently, according to Accern Sentiment. The research group scores the sentiment of media coverage by monitoring more than twenty million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. AngioDynamics earned a media sentiment score of 0.05 on Accern's scale. They also gave news articles about the medical instruments supplier an impact score of 43.00 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock's share price in the immediate future. Who are AngioDynamics' major shareholders? AngioDynamics' stock is owned by a number of of retail and institutional investors. Top institutional investors include Fenimore Asset Management Inc. (1.54%), First National Bank of Omaha (0.09%), Campbell & CO Investment Adviser LLC (0.06%) and Port Capital LLC (0.04%). Company insiders that own AngioDynamics stock include Avista Capital Partners Gp, Ll, David F Burgstahler, James C Clemmer and Jan Stern Reed. View Institutional Ownership Trends for AngioDynamics. Which institutional investors are selling AngioDynamics stock? ANGO stock was sold by a variety of institutional investors in the last quarter, including Fenimore Asset Management Inc.. View Insider Buying and Selling for AngioDynamics. Which institutional investors are buying AngioDynamics stock? ANGO stock was purchased by a variety of institutional investors in the last quarter, including First National Bank of Omaha, Campbell & CO Investment Adviser LLC and Port Capital LLC. Company insiders that have bought AngioDynamics stock in the last two years include James C Clemmer and Jan Stern Reed. View Insider Buying and Selling for AngioDynamics. How do I buy shares of AngioDynamics? Shares of ANGO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is AngioDynamics' stock price today? One share of ANGO stock can currently be purchased for approximately $20.60. How big of a company is AngioDynamics? AngioDynamics has a market capitalization of $758.18 million and generates $344.29 million in revenue each year. The medical instruments supplier earns $5 million in net income (profit) each year or $0.74 on an earnings per share basis. AngioDynamics employs 1,250 workers across the globe. How can I contact AngioDynamics? AngioDynamics' mailing address is 14 PLAZA DRIVE, LATHAM NY, 12110. The medical instruments supplier can be reached via phone at 518-795-1400 or via email at [email protected] MarketBeat Community Rating for AngioDynamics (NASDAQ ANGO)Community Ranking: 2.1 out of 5 ( )Outperform Votes: 218 (Vote Outperform)Underperform Votes: 294 (Vote Underperform)Total Votes: 512MarketBeat's community ratings are surveys of what our community members think about AngioDynamics and other stocks. Vote "Outperform" if you believe ANGO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ANGO will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 7/15/2018 by MarketBeat.com StaffFeatured Article: Are Wall Street analysts' stock ratings worth following?